Results 161 to 170 of about 121,968 (199)

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review. [PDF]

Front Med (Lausanne)
Phongphithakchai A, Klangbud WK, Srithongkul T, Raksasuk S, Chatatikun M.   +4 more
europepmc   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

<i>Yi-Shen-Hua-Shi</i> granule added to supportive care reduces proteinuria in IgA nephropathy: a multicenter randomized controlled trial. [PDF]

Ren Fail
Chen Y, Tang J, Li X, Zhang X, Zhang F, Zheng R, Shen L, Rong S, Xie J, Wang Q, Zhong Y.   +10 more
europepmc   +1 more source

PLIN5 Protects Against Ang II‐Induced Podocyte Lipotoxicity by Interacting With FKBP8 and Preserving Lipid Droplet–Mitochondria Contact

Cell Proliferation, EarlyView.
PLIN5‐FKBP8 tethers lipid droplets to mitochondria to counteract Ang II‐induced lipotoxicity. ABSTRACT Chronic kidney disease (CKD) remains a major global health challenge. Angiotensin II (Ang II)‐induced lipotoxicity is an important contributor to podocyte injury.
Ping Wang, Wenjie Chen, Jingjing Ke, Hongtu Hu, Zhuan Peng, Yue Qi, Guohua Ding, Jijia Hu   +7 more
wiley   +1 more source

Overweight/obesity accelerates proteinuria progression in type 2 diabetes post-COVID-19: a comparison with a pre-pandemic uninfected cohort. [PDF]

Front Endocrinol (Lausanne)
Wu J, Gu L, Zhen Q, Yang J, Wang Y, Zhang Y, Chen Y, Liu F, Ding X, Wang Y, Li N.   +10 more
europepmc   +1 more source

Membranous nephropathy secondary to very early-onset inflammatory bowel disease in a 3-year-old boy: case report. [PDF]

CEN Case Rep
Aoyama S, Yamamura T, Horinouchi T, Kimura Y, Inoki Y, Sakakibara N, Nagano C, Ishimori S, Kameoka Y, Kajihara K, Miyauchi H, Ku Y, Miyazaki H, Okamoto N, Yoshikawa N, Nozu K.   +15 more
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons, Husam Ghanim, James G. Boyle, Nicola Greenlaw, Ajay Chaudhuri, Manav A. Batra, Robert S. Lindsay, Lisa Jolly, Caroline Bonner, Alex McConnachie, John R. Petrie, Paresh Dandona   +11 more
wiley   +1 more source

Evaluation of clinicopathological features of renal biopsies in non-lupus rheumatic diseases: a university hospital experience. [PDF]

Ren Fail
Sezen M, Yildiz A, Aytaç-Vuruşkan B, Ortaç H, Güllülü M, Ersoy A.   +5 more
europepmc   +1 more source

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink, Gozewijn D. Laverman, Hiddo J. L. Heerspink   +2 more
wiley   +1 more source